BioAtla (NASDAQ:BCAB) Issues Earnings Results, Beats Estimates By $0.20 EPS

BioAtla (NASDAQ:BCAB) posted its quarterly earnings results on Tuesday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.20, FiscalAI reports. The firm had revenue of $2.00 million for the quarter, compared to the consensus estimate of $0.70 million.

BioAtla Stock Performance

NASDAQ:BCAB opened at $0.16 on Wednesday. The company has a market cap of $10.22 million, a price-to-earnings ratio of -0.14 and a beta of 1.08. BioAtla has a fifty-two week low of $0.13 and a fifty-two week high of $1.43. The stock has a fifty day moving average price of $0.20 and a 200-day moving average price of $0.53.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Millennium Management LLC bought a new stake in shares of BioAtla in the 3rd quarter valued at about $235,000. Vanguard Group Inc. raised its position in shares of BioAtla by 9.1% during the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after acquiring an additional 162,647 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of BioAtla by 968.9% in the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after acquiring an additional 1,531,994 shares during the period. Marshall Wace LLP bought a new stake in BioAtla in the fourth quarter valued at approximately $508,000. Finally, Jane Street Group LLC boosted its holdings in BioAtla by 55.4% in the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after acquiring an additional 123,597 shares during the last quarter. 77.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAtla in a report on Friday, January 9th. Rodman & Renshaw began coverage on BioAtla in a report on Tuesday, January 13th. They set a “buy” rating and a $4.00 target price on the stock. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.